Mimetas

Executive Summary

Mimetas, a Netherlands-based biotechnology company founded in 2013, is a pioneer in Organ-on-a-Chip technology, developing advanced platforms to revolutionize drug discovery and development. Its flagship OrganoPlate® technology enables the creation of highly predictive 3D human tissue models that more accurately mimic human physiology than traditional 2D cell cultures or animal models. By providing scalable, physiologically relevant testing for drug efficacy, safety, and pharmacokinetics, Mimetas aims to reduce reliance on animal testing and accelerate the drug development pipeline. The company's platform is already being adopted by pharmaceutical companies and contract research organizations (CROs) for early-stage drug screening. Despite being in the pre-clinical stage, Mimetas has established itself as a key player in the Organ-on-a-Chip market, attracting interest from major drug developers. The company's technology holds promise not only for more efficient drug discovery but also for personalized medicine applications. However, as a private company with no disclosed total funding, its growth trajectory will depend on securing strategic partnerships and further capital infusion to scale its technology and capture market share. With increasing regulatory emphasis on reducing animal testing, Mimetas is well-positioned to benefit from industry tailwinds, though near-term revenue visibility remains limited.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Top-20 Pharmaceutical Company60% success
• Q3 2026Series B or C Funding Round Closing65% success
• Q4 2026Launch of Next-Generation OrganoPlate with Expanded Capabilities50% success